Curaxys offers a comprehensive technological package to the manufacturing of lab and pilot-scale, phase I/II clinical trials and commercial-stage biopharmaceutical products, primary recombinant protein and monoclonal antibody, by employing superior GMP compliant services that enable cost-effective. Curaxys is able to perform the complete development programme or individual work package:

  • Cell lines developed from cDNA
  • Proof of Concept
  • Assay Tech Transfer
  • Assay functional, structural and activity
  • Master / Working Cell Bank
  • Cell Culture Process Development
  • Protein Purification
  • Engineering / Pilot Run
  • cGMP Manufacturing for phase I/II clinical trials
  • Commercial production
  • Regulatory-compliant GMP facilities
  • Complete process R&D service offering


More on Curaxys
We focus on the research, production and commercialization of recombinant proteins added value through the utilization of CuraMab® with specific human cell lines
Our expression system allows us to reach of recombinant protein levels that are clearly above those currently available.
We developed a downstream technological platform on the basis of our own laboratory data.

Latest News

  • Curaxys obtains financing for the purchase of equipment with the help granted by Innplanta 2012
  • Curaxys hires five more technologists.
  • One of the largest biopharmaceutical projects in Europe to be started at Tecnobahía.
  • Innovaxis, a novel company for “custom medicine”
  • Strategic Alliance for cancer disease
  • UCA and Curaxys create a Cathedra in biopharmaceuticals in order to research biosimilar proteins
  • Curaxys is ranked among the world top ten companies in the research of biologic generic medicines

  • Copyright 2012 Curaxys. All Rights Reserved
    Legal Advice